Cytokine therapy with interferon-α (IFN-α) and interleukin-2 (IL-2) dominated treatment from the late 1980s until 2007, when the introduction of VEGF tyrosine kinase inhibitors (TKIs) revolutionised RCC treatment. This evidence concerns the gene IL2 and renal cell carcinoma.